For some time now, hyaluronic acid (HA) viscosupplement injections (aka intra-articular (IA) HA injections) have become a standard and an integral part of the physician’s armamentarium in the treatment continuum for an ever-growing number of patients suffering from knee osteoarthritis (OA). With OA universally established as the most prevalent form of arthritis afflicting the US population, SmartTRAK estimates that approximately 2.3 million HA injection procedures will be performed for knee OA alone. Yet, confusion and debates persist over the efficacy of HA therapy, product composition and source of the HA, volume and number of injections, treatment cost and, more recently, regulatory classification for HA products. SmartTRAK believes that the plethora of studies on the use of HA injection that show varied results is ...
To download and read the complete article by Freddy Buntoum, Sr. Analyst, Orthobiologics and Regenerative Medicine at SmartTRAK, please click the button below.
SmartTRAK is the leading source of competitive intelligence used by the top ten global wound care & orthopedics companies. If you would like a demo of what SmartTRAK has to offer and how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.